Deliver Your News to the World

SmallCapNewsRelease:(OTCBB: PROT) To Work with the University of Miami on Clinical Studies


JERICHO, NY—(SmallCapNewsRelease)—December 14, 2011, Proteonomix, Inc. (OTCBB: PROT) a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, recently announced they have formed an agreement with the University of Miami to conduct a clinical study entitled “UMK 121 in Patients with Liver Disease”. The university will pay all expenses associated with the clinical study and Proteonomix will contribute $105,000.
Pre-clinical studies have been conducted in rodents and a large animal model to confirm the potential of the UMK-121 technology to mobilize Stromal Stem Cells (“SSCs”) into the peripheral blood of animals, thereby making the SSCs available for therapeutic uses.
The company believes clinical trials of the UMK-121 will yield favorable results that trial will catapult Proteonomix into the forefront of the plethora of development stage companies with stem cell technologies.
To view the entire press release, please visit
SmallCapNewsRelease gainers are eOn Communications Corp (NASDAQ: EONC) Accelr8 Technology Corp (NYSE: AXK) MER Telemanagement Solutions (NASDAQ: MTSL) Ampio Pharma (NASDAQ: AMPE) Albany Molcular Research (NASDAQ: AMRI) ViroPharma Inc (NASDAQ: VPHM) Lantronix, Inc (NASDAQ: LTRX) Seneca Foods Corp (NASDAQ: SENEB)
SmallCapNewsRelease decliners are Sequans Communications (NASDAQ: SQNS) First Solar (NASDAQ: FSLR) HyperDynamics Corp (NYSE: HDY) Silicon Graphics International (NYSE: SGI) SunPower Corp (NASDAQ: SPWR) BioSante Pharma (NASDAQ: BPAX) Arabian American Development (NASDAQ: ARSD) Adeona Pharma (NYSE: AEN)
Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid SmallCapNewsRelease one thousand two hundred and ninety five dollars for the publication and circulation of this news release. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation do no trading of any kind and send no Faxes or emails.


 Clinical Trials

This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.